TFAP2C and breast cancer: Silencing TFAP2C reduced malignant behaviors, decreased YAP, phosphorylated YAP (p-YAP) and β-catenin levels, and increased apoptosis in both cisplatin-sensitive and cisplatin-resistant BC cells.